Your search for Warfarin returned 37 results

Overtreatment with anticoagulation for atrial fibrillation may double risk for dementia.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Major bleeding events are rare in patients with stable coronary artery disease (CAD); however, concomitant antiplatelet therapy (APT) when oral anticoagulation is required increases bleeding risk – an independent predictor of mortality – and should be reconsidered in select patients.

Unstable anticoagulation predicts warfarin adverse effects regardless of time in therapeutic range.

In patients with atrial fibrillation taking warfarin, use of selective serotonin reuptake inhibitor (SSRI) medications is associated with an increased risk of major hemorrhage.

Most U.S. patients with myocardial infarction (MI) are discharged on high-dose aspirin, but there is considerable variation across hospitals in proportion prescribed aspirin at discharge and in dosage.

Among patients with newly diagnosed atrial fibrillation (AF), the use of digoxin is associated with increased risk of death.

For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.

Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.

For patients undergoing lower-extremity arthroplasty, a mobile compression device is noninferior to pharmacological protocols for the prevention of venous thromboembolism.